Study offers a differentiated patient-specific solution in minimal residual disease t

[News]

Exact Sciences Corp. today announced that it has acquired a worldwide exclusive license to the proprietary TARDIS technology from the Translational Genomics Research Institute (TGen), an affiliate of City of Hope.

More... (https://www.news-medical.net/news/20210115/Study-offers-a-differentiated-patient-specific-solution-in-minimal-residual-disease-testing.aspx)